SEARCH

SEARCH BY CITATION

References

  • 1
    Qaseem A, Snow V, Denberg TD et al. Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2009; 151: 639679
  • 2
    Magheli A, Burnett AL. Erectile dysfunction following prostatectomy: prevention and treatment. Nat Rev Urol 2009; 6: 415427
  • 3
    Glickman L, Godoy G, Lepor H. Changes in continence and erectile function between 2 and 4 years after radical prostatectomy. J Urol 2009; 181: 731735
  • 4
    Rabbani F, Stapleton AM, Kattan MW, Wheeler TM, Scardino PT. Factors predicting recovery of erections after radical prostatectomy. J Urol 2000; 164: 19291934
  • 5
    Hatzimouratidis K, Burnett AL, Hatzichristou D, McCullough AR, Montorsi F, Mulhall JP. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. Eur Urol 2009; 55: 334347
  • 6
    McCullough AR, Levine LA, Padma-Nathan H. Return of nocturnal erections and erectile function after bilateral nerve-sparing radical prostatectomy in men treated nightly with sildenafil citrate: subanalysis of a longitudinal randomized double-blind placebo-controlled trial. J Sex Med 2008; 5: 476484
  • 7
    Mulhall JP. The role and structure of a postradical prostatectomy penile rehabilitation program. Curr Urol Rep 2009; 10: 219225
  • 8
    Garcia FJ, Brock G. Current state of penile rehabilitation after radical prostatectomy. Curr Opin Urol 2010; 20: 234240
  • 9
    Rambhatla A, Kovanecz I, Ferrini M, Gonzalez-Cadavid NF, Rajfer J. Rationale for phosphodiesterase 5 inhibitor use post-radical prostatectomy: experimental and clinical review. Int J Impot Res 2008; 20: 3034
  • 10
    Shindel AW. 2009 update on phosphodiesterase type 5 inhibitor therapy part 1: recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME). J Sex Med 2009; 6: 17941808; quiz 93: 809–10
  • 11
    Montorsi F, Brock G, Lee J et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 2008; 54: 924931
  • 12
    Padma-Nathan H, McCullough AR, Levine LA et al. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res 2008; 20: 479486
  • 13
    Mulhall JP. Does on-demand vardenafil improve erectile function recovery after radical prostatectomy? Nat Clin Pract Urol 2009; 6: 1415
  • 14
    Mulhall JP, Parker M, Waters BW, Flanigan R. The timing of penile rehabilitation after bilateral nerve-sparing radical prostatectomy affects the recovery of erectile function. BJU Int 2010; 105: 3741
  • 15
    Bannowsky A, Schulze H, van der Horst C, Hautmann S, Junemann KP. Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil. BJU Int 2008; 101: 12791283
  • 16
    Novara G, Ficarra V. Re: Francesco Montorsi, Gerald Brock, Jay Lee, et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 2008; 54: 924–31. Eur Urol 2009; 55: e9596; author reply e97–8
  • 17
    Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822830
  • 18
    Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000; 56: 899905
  • 19
    Alemozaffar M, Regan MM, Cooperberg MR et al. Prediction of erectile function following treatment for prostate cancer. JAMA 2011; 306: 12051214
  • 20
    Moskovic DJ, Alphs H, Nelson CJ et al. Subjective characterization of nerve sparing predicts recovery of erectile function after radical prostatectomy: defining the utility of a nerve sparing grading system. J Sex Med 2011; 8: 255260
  • 21
    Levinson AW, Pavlovich CP, Ward NT, Link RE, Mettee LZ, Su LM. Association of surgeon subjective characterization of nerve sparing quality with potency following laparoscopic radical prostatectomy. J Urol 2008; 179: 15101514
  • 22
    Meinert CL, Tonascia S. Clinical Trials: Design, Conduct, and Analysis. New York: Oxford University Press, 1986
  • 23
    Lachin JM. Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials 1981; 2: 93113
  • 24
    Littell RC, Pendergast J, Natarajan R. Modelling covariance structure in the analysis of repeated measures data. Stat Med 2000; 19: 17931819
  • 25
    Cappelleri JC, Siegel RL, Osterloh IH, Rosen RC. Relationship between patient self-assessment of erectile function and the erectile function domain of the international index of erectile function. Urology 2000; 56: 477481
  • 26
    Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988; 44: 10491060
  • 27
    Shafer JL. Analysis of Incomplete Multivariate Data. New York: Chapman & Hall, 1997
  • 28
    Teloken P, Mesquita G, Montorsi F, Mulhall J. Post-radical prostatectomy pharmacological penile rehabilitation: practice patterns among the international society for sexual medicine practitioners. J Sex Med 2009; 6: 20322038
  • 29
    Levinson AW, Ward NT, Sanda MG et al. Comparison of validated instruments measuring sexual function in men. Urology 2010; 76: 380386
  • 30
    Montorsi F, Nathan HP, McCullough A et al. Tadalafil in the Treatment of Erectile Dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. J Urol 2004; 172: 10361041